Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

NDAQ:MNMD - Post Discussion

Mind Medicine (MindMed) Inc > HAVN to be included in psychedelic ETF
View:
Post by Idvhmz123 on Jan 27, 2021 6:06am

HAVN to be included in psychedelic ETF

HAVN Life to be included in psychedelics ETF 2021-01-22 08:52 ET - News Release Mr. Tim Moore reports HAVN LIFE SCIENCES ANNOUNCES INCLUSION IN FIRST PSYCHEDELIC EXCHANGE TRADED FUND HAVN Life Sciences Inc. will be included in the first psychedelics exchange-traded fund (ETF). The ETF will begin traded on the Neo Exchange on Jan. 26, 2021. HAVN Life is one of 17 companies that met the minimum requirements of listing within the ETF. The ETF is managed by Horizons ETF Management, one the largest ETF providers in Canada, with over $16-billion in assets under management across 93 ETFs. Horizons also brought the first cannabis ETF to market in 2017 and continues to lead the industry with ETFs in emerging industries. Inclusion into an ETF is an important milestone for HAVN Life's investors and stakeholders. The ETF will bring additional exposure to potential new investors, as well as generate value for existing shareholders. Tim Moore remarked: "Our team is excited to be included in Horizons Psychedelics ETF, which will allow HAVN Life to become available to a wider audience of the investment community. We continue to work to provide added shareholder value to our stakeholders." About HAVN Life Sciences Inc. HAVN Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. We seek Safe Harbor.
Be the first to comment on this post